Evommune, Inc. (EVMN)
| Market Cap | 215.21M |
| Revenue (ttm) | 10.00M +233.3% |
| Net Income | -94.67M |
| EPS | -4.15 |
| Shares Out | 36.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,084 |
| Open | 5.90 |
| Previous Close | 5.77 |
| Day's Range | 5.81 - 6.00 |
| 52-Week Range | 5.64 - 33.20 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.33 (+276.56%) |
| Est. Earnings | Nov 7, 2026 |
About EVMN
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Financial Performance
In 2025, Evommune's revenue was $13.00 million, an increase of 85.71% compared to the previous year's $7.00 million. Losses were -$68.87 million, 0.82% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for EVMN stock is "Buy." The 12-month stock price target is $22.33, which is an increase of 276.56% from the latest price.
News
Evommune initiated with a Neutral at UBS
UBS analyst Alice Nettleton initiated coverage of Evommune (EVMN) with a Neutral rating and $8 price target Following the positive Phase 2a data, UBS views EVO301 as a credible emerging…
Evommune presents Phase 2a PoC data on EVO301 at EADV Congress
Evommune (EVMN) shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis during a late-breaking oral presentation at the European A...
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Revised summary: The company advances a diversified pipeline with two co-lead assets: an IL-18 biologic for atopic dermatitis (strong Phase IIa, moving to IIb) and an oral MRGPRX2 inhibitor in Phase IIb for migraine. Other programs include a TLR7/8 inhibitor and STAT6 degrader. Financially robust, it leverages AI and adapts to industry trends.
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on September 15, 2026.
Evommune price target lowered to $23 from $28 at Clear Street
Clear Street lowered the firm’s price target on Evommune (EVMN) to $23 from $28 and keeps a Buy rating on the shares. The firm has updated its model after yesterday’s…
Evommune price target lowered to $18 from $32 at Raymond James
Raymond James lowered the firm’s price target on Evommune (EVMN) to $18 from $32 and keeps an Outperform rating on the shares. Evommune’s EVO756 AD failure, following the CSU miss,…
Evommune price target lowered to $22 from $28 at Leerink
Leerink lowered the firm’s price target on Evommune (EVMN) to $22 from $28 and keeps an Outperform rating on the shares. The company announced negative results from the Phase 2b…
Evommune price target lowered to $21 from $29 at RBC Capital
RBC Capital lowered the firm’s price target on Evommune (EVMN) to $21 from $29 and keeps an Outperform rating on the shares. EVO-756’s AD failure is disappointing and raises questions…
Evommune scraps eczema drug after trial miss, shares plunge
Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.
Evommune Phase 2b EV0756 trial did not meet primary and secondary endpoints
Evommun “announced top-line results from its randomized, double-blind, placebo controlled dose-ranging Phase 2b trial evaluating the efficacy and safety of oral Mas-related G-protein coupled receptor ...
Evommune down 31% at $9 after Phase 2b EVO-756 study results
17:46 EDT Evommune (EVMN) down 31% at $9 after Phase 2b EVO-756 study results
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune initiated with a Buy at Needham
Needham initiated coverage of Evommune (EVMN) with a Buy rating and $28 price target Evommune has a “promising I&I pipeline,” notably EVO301, which has demonstrated proof-of-concept efficacy on par or...
Evommune price target lowered to $29 from $30 at RBC Capital
RBC Capital lowered the firm’s price target on Evommune (EVMN) to $29 from $30 and keeps an Outperform rating on the shares. Despite the stock’s recovery from lows, shares remain…
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers...
Evommune Slides: Corporate presentation
Evommune has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Evommune Quarterly report: Q2 2026
Evommune has published its Q2 2026 quarterly earnings report on August 6, 2026.
Evommune Earnings release: Q2 2026
Evommune released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Evommune initiates Phase 2b trial of EVO756
Evommune (EVMN) announced the first patient was dosed in its Phase 2b clinical trial evaluating EVO756, for the prophylactic treatment of migraine. “Initiating this migraine trial is an exciting miles...
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommune”), a clinical-stage biotechnology company developing innovative therapies that target key driver...
Evommune participates in a conference call with Cantor
Cantor holds a conference call with management on July 31 at 11:30 am hosted by Cantor.Webcast Link
Clear Street sees attractive point into Evommune after selloff
Clear Street views the recent selloff in shares of Evommune (EVMN) as creating an attractive entry point with the Phase 2b atopic dermatitis data for EVO756 expected in Q3. Positive…
Septerna price target lowered to $45 from $52 at Guggenheim
Guggenheim analyst Seamus Fernandez lowered the firm’s price target on Septerna (SEPN) to $45 from $52 and keeps a Buy rating on the shares after Evommune (EVMN) announced top-line results…